ShareValue.ai

ShareValue scores for 1349.HK: Valuation 51, Quality 61, Growth 27, Health 72.

1349.HK
HKEX

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

HK$2.37(-1.25%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 15%
Valuation
51
Fair Value
Price vs Value
Quality
61
Moderate
Business Strength
Growth
27
Weak
Revenue & Earnings
Health
72
Healthy
Financial Stability
Momentum
22
Bearish
Price Trend

Company Details

About

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Score Analysis

AI Investment Thesis

Data as of:Jul 10, 2026
|
Last calculated:Jul 10, 2026